A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

Clinical trial NCT07069309 · COMPLETED

Trial details

NCT number: NCT07069309
Sponsor: BioNTech SE
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

COVID-19 SARS-COV-2 Infection

Start date: 2025-07-08
Primary completion: 2026-05-01
Enrollment: 774

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.